Stanford Health Care

Stanford Health Care was paid $264.82M by Medicaid between Jan 2018 and Dec 2024, across 782 billing codes. Its largest line is J9271, Injection, pembrolizumab, 1 mg — 9.3% of everything it billed.

33Billing provider infoSTANFORD HEALTH CARE
STANFORD, CA 94305

33aNPI1871543215assigned 05/10/2006

33bProvider typeGeneral Acute Care Hospital

28Total paid$264.82M

24GClaims3,937,825

24DCodes billed782

24AFirst – last monthJan 2018 – Dec 2024

Compared with peers

Next to other General Acute Care Hospital providers in California

Rank by total paid#1 of 410

Median peer was paid$6.90M

This provider vs. median38×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	419,946	$25.49M
2019	449,608	$25.48M
2020	430,655	$23.41M
2021	568,826	$32.15M
2022	654,670	$44.17M
2023	751,116	$49.83M
2024incomplete	663,004	$64.30M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
J9271	Injection, pembrolizumab, 1 mg	9.3%	1,850	1,439	$24.52M
0450	Emergency room services	4.3%	125,650	112,093	$11.28M
0510		3.0%	226,873	180,117	$8.06M
78815	Positron emission tomography (PET) for limited area imaging	2.8%	5,499	5,443	$7.54M
J9035	Injection, bevacizumab, 10 mg	2.7%	3,421	1,702	$7.02M
70553	Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences	2.6%	9,046	8,953	$6.93M
77386		2.3%	12,482	1,337	$6.20M
74177	Computed tomography, abdomen and pelvis; with contrast material	2.2%	21,794	21,223	$5.80M
99284	Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity	2.1%	10,536	9,389	$5.50M
J9299	Injection, nivolumab, 1 mg	2.0%	798	433	$5.18M
J2505	Injection, pegfilgrastim, 6 mg	1.9%	1,148	830	$4.98M
80053	Comprehensive metabolic panel	1.7%	219,562	164,799	$4.51M

770 more codes

J2350	Injection, ocrelizumab, 1 mg	1.6%	158	$4.28M
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	1.5%	26,840	$4.10M
J9355	Injection, trastuzumab, excludes biosimilar, 10 mg	1.5%	867	$3.99M
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	1.5%	49,751	$3.87M
J0897	Injection, denosumab, 1 mg	1.4%	1,966	$3.81M
J0585	Injection, onabotulinumtoxina, 1 unit	1.4%	4,107	$3.77M
Q3014	Telehealth originating site facility fee	1.3%	174,959	$3.45M
99283	Emergency room visit (moderate)	1.2%	7,155	$3.13M
J1745	Injection, infliximab, excludes biosimilar, 10 mg	1.1%	1,170	$2.98M
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	1.1%	1,258	$2.91M
93306	Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete	1.0%	12,209	$2.77M
J2323	Injection, natalizumab, 1 mg	1.0%	379	$2.72M
99281	Emergency department visit for the evaluation and management, self-limited or minor	1.0%	8,254	$2.68M
99211	Office or other outpatient visit for the evaluation and management of an established patient, minimal severity	1.0%	67,625	$2.67M
71260	Computed tomography, thorax, diagnostic; with contrast material	<1%	12,260	$2.58M
G0463	Hospital outpatient clinic visit for assessment and management of a patient	<1%	114,658	$2.54M
96374	Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance	<1%	31,784	$2.40M
J0178	Injection, aflibercept, 1 mg	<1%	2,470	$2.35M
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	207,403	$2.35M
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	<1%	20,505	$2.12M
78816		<1%	1,191	$1.97M
74183		<1%	5,316	$1.86M
71275	Computed tomographic angiography, chest, with contrast material	<1%	5,298	$1.82M
96375	Therapeutic injection; each additional sequential IV push	<1%	33,200	$1.75M
96413	Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance	<1%	26,730	$1.73M
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	<1%	958	$1.73M
70450	Computed tomography, head or brain; without contrast material	<1%	9,535	$1.72M
93005	Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report	<1%	51,868	$1.66M
99285	Emergency room visit (most serious)	<1%	6,478	$1.54M
99202	Office or other outpatient visit for the evaluation and management of a new patient, straightforward	<1%	2,657	$1.54M
A9552	Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries	<1%	5,186	$1.51M
70551	Magnetic resonance imaging, brain; without contrast material	<1%	2,971	$1.46M
72197		<1%	3,769	$1.35M
74174		<1%	2,060	$1.32M
99070		<1%	162,369	$1.21M
77300		<1%	2,747	$1.20M
72156		<1%	1,211	$1.20M
J9144	Injection, daratumumab, 10 mg and hyaluronidase-fihj	<1%	151	$1.19M
77295		<1%	1,386	$1.18M
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	<1%	16,047	$1.13M
77301		<1%	924	$1.09M
72148	Magnetic resonance imaging, lumbar spine; without contrast material	<1%	2,987	$1.07M
77373		<1%	710	$1.06M
J1459	Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg	<1%	365	$1.06M
71250		<1%	6,142	$1.06M
72157		<1%	1,198	$1.03M
96361	Intravenous infusion, hydration; each additional hour	<1%	18,402	$997K
72125	Computed tomography, cervical spine; without contrast material	<1%	3,503	$866K
93975		<1%	3,654	$845K
71046	Radiologic examination, chest; 2 views	<1%	26,050	$829K
72158		<1%	931	$823K
96360	Intravenous infusion, hydration; initial, 31 minutes to 1 hour	<1%	9,002	$817K
77334		<1%	3,594	$755K
72141		<1%	1,697	$746K
70543		<1%	1,687	$736K
99201		<1%	1,539	$712K
97139		<1%	33,873	$692K
83735		<1%	43,619	$690K
84443	Thyroid stimulating hormone (TSH)	<1%	33,209	$686K
P9040	Red blood cells, leukocytes reduced, irradiated, each unit	<1%	2,670	$683K
C9803	Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	32,283	$681K
73721	Magnetic resonance imaging, any joint of lower extremity; without contrast material	<1%	1,845	$673K
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	<1%	21,920	$649K
87632		<1%	3,711	$633K
0762		<1%	8,427	$617K
95810	Polysomnography; sleep staging with 4 or more additional parameters	<1%	2,028	$591K
70498		<1%	1,579	$579K
J1453	Injection, fosaprepitant, 1 mg	<1%	4,396	$577K
84484		<1%	28,980	$565K
J9305	Injection, pemetrexed, not otherwise specified, 10 mg	<1%	283	$562K
99231	Subsequent hospital care, per day, straightforward or low complexity	<1%	9,491	$554K
Q9967	Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	<1%	38,669	$552K
93970		<1%	3,280	$551K
J9312	Injection, rituximab, 10 mg	<1%	129	$544K
0370		<1%	3,133	$533K
82803		<1%	14,258	$526K
70496		<1%	1,608	$519K
J3490	Unclassified drugs	<1%	52,858	$513K
80197		<1%	27,871	$508K
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour	<1%	6,859	$506K
96367		<1%	7,742	$500K
0250		<1%	25,049	$491K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	7,202	$491K
87507		<1%	1,103	$490K
76700	Ultrasound, abdominal, real time with image documentation; complete	<1%	6,449	$485K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	9,489	$470K
A9577	Injection, gadobenate dimeglumine (multihance), per ml	<1%	11,514	$460K
76705	Ultrasound, abdominal, real time with image documentation; limited	<1%	6,403	$436K
96417		<1%	7,214	$430K
77412		<1%	5,547	$429K
87497		<1%	8,399	$422K
96415		<1%	7,253	$419K
0270		<1%	77,702	$411K
93976		<1%	2,641	$408K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	14,625	$401K
67028	Intravitreal injection of a pharmacologic agent	<1%	9,768	$401K
93350		<1%	3,081	$396K
70544		<1%	1,476	$394K
86850		<1%	25,112	$388K
70486		<1%	1,719	$375K
92557		<1%	6,976	$365K
86832		<1%	2,480	$365K
86923		<1%	3,301	$360K
93971		<1%	3,295	$359K
81382		<1%	471	$358K
81001		<1%	58,224	$356K
88185		<1%	862	$351K
77338		<1%	1,018	$351K
72131		<1%	1,504	$348K
74160		<1%	1,389	$347K
93325		<1%	3,156	$344K
93017		<1%	3,968	$341K
71045	Radiologic examination, chest; single view	<1%	18,022	$332K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	1,190	$332K
97750		<1%	7,978	$323K
77336		<1%	5,486	$322K
Z7502		<1%	8,981	$321K
95811		<1%	1,174	$316K
99291	Critical care, evaluation and management of the critically ill patient, first 30-74 minutes	<1%	583	$310K
93308		<1%	2,795	$309K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	<1%	617	$306K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	5,476	$303K
76856	Ultrasound, pelvic (nonobstetric), real time with image documentation; complete	<1%	3,906	$303K
76830	Ultrasound, transvaginal	<1%	4,026	$297K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	5,475	$296K
70491		<1%	1,203	$290K
88341		<1%	1,594	$283K
99199	Unlisted special service, procedure or report	<1%	5,283	$279K
86833		<1%	2,461	$278K
72128		<1%	966	$273K
87040		<1%	6,938	$272K
87086	Culture, bacterial; quantitative colony count, urine	<1%	22,532	$271K
93303	Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study	<1%	1,259	$269K
85027		<1%	30,413	$267K
75574		<1%	1,002	$265K
83605		<1%	15,462	$264K
81378		<1%	621	$262K
80061	Lipid panel	<1%	21,863	$261K
93320		<1%	2,969	$258K
87799		<1%	4,706	$258K
86900		<1%	26,731	$254K
86480		<1%	5,402	$253K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	2,755	$253K
83970		<1%	6,090	$251K
74176	Computed tomography, abdomen and pelvis; without contrast material	<1%	2,042	$251K
83036	Hemoglobin; glycosylated (A1C)	<1%	27,148	$250K
86901		<1%	26,219	$250K
Q5107	Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg	<1%	141	$249K
0272		<1%	1,921	$248K
83880		<1%	9,102	$246K
V5298	Hearing aid, not otherwise classified	<1%	182	$245K
83690		<1%	21,348	$244K
80048	Basic metabolic panel (calcium, ionized)	<1%	22,602	$244K
94640	Pressurized or nonpressurized inhalation treatment for acute airway obstruction	<1%	7,406	$242K
77290		<1%	1,242	$240K
J1610	Injection, glucagon hydrochloride, per 1 mg	<1%	1,130	$240K
74178		<1%	978	$239K
73221		<1%	648	$234K
94375		<1%	5,207	$231K
85610		<1%	35,237	$231K
84100		<1%	26,410	$219K
77470		<1%	790	$218K
77067	Screening mammography, bilateral, including computer-aided detection	<1%	3,395	$213K
82728		<1%	13,128	$206K
85730		<1%	17,395	$205K
76536		<1%	3,148	$205K
77049		<1%	354	$202K
78830		<1%	431	$197K
97799		<1%	9,816	$187K
94729		<1%	4,024	$186K
G0378	Hospital observation service, per hour	<1%	3,057	$186K
J2469	Injection, palonosetron hcl, 25 mcg	<1%	3,317	$184K
0121		<1%	18	$182K
86140		<1%	19,168	$181K
0760		<1%	5,857	$180K
76770		<1%	2,394	$180K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	<1%	123	$176K
77066	Tomosynthesis, mammo	<1%	1,808	$173K
76642		<1%	2,803	$173K
93296		<1%	5,034	$170K
84439		<1%	13,452	$168K
73630		<1%	5,444	$160K
T1999	Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks"	<1%	38,748	$159K
73610		<1%	4,271	$153K
73030		<1%	5,346	$148K
88342		<1%	3,430	$147K
0681		<1%	283	$146K
70549		<1%	365	$144K
93880		<1%	1,143	$141K
82378		<1%	6,176	$140K
87631		<1%	2,596	$138K
0710		<1%	1,657	$137K
96416		<1%	1,451	$136K
78452	Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress	<1%	372	$136K
83615		<1%	13,857	$134K
82962		<1%	16,812	$134K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	1,750	$130K
96401		<1%	3,425	$130K
99152		<1%	2,721	$129K
94060		<1%	2,377	$128K
87517		<1%	3,233	$126K
81455		<1%	57	$125K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	2,430	$123K
80306		<1%	3,730	$122K
P9073	Platelets, pheresis, pathogen-reduced, each unit	<1%	242	$118K
83550		<1%	13,499	$118K
85379		<1%	4,964	$109K
82024		<1%	2,681	$107K
87340		<1%	6,757	$106K
87186		<1%	7,724	$105K
90677		<1%	699	$104K
V2632	Posterior chamber intraocular lens	<1%	901	$104K
82533		<1%	4,064	$104K
87077		<1%	11,272	$103K
87150		<1%	3,990	$103K
96402		<1%	3,498	$102K
87486		<1%	3,488	$101K
76817	Ultrasound, pregnant uterus, real time with image documentation, transvaginal	<1%	1,342	$101K
87581		<1%	3,486	$101K
92507	Treatment of speech, language, voice, communication, and/or auditory processing disorder	<1%	2,762	$101K
86803		<1%	5,771	$101K
83540		<1%	13,938	$101K
84403		<1%	3,257	$100K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	4,890	$98K
97110	Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion	<1%	12,170	$98K
80180		<1%	8,576	$98K
99153	Mod sedat endo service >5yrs	<1%	1,993	$97K
78264		<1%	402	$96K
93246		<1%	3,936	$95K
96411		<1%	1,961	$94K
73590		<1%	2,070	$94K
Z7500		<1%	4,207	$94K
0761		<1%	1,113	$94K
92550		<1%	4,269	$94K
72146		<1%	230	$93K
82784		<1%	7,458	$93K
73110		<1%	2,991	$93K
J2405	Injection, ondansetron hydrochloride, per 1 mg	<1%	15,475	$91K
97165		<1%	2,426	$90K
73700		<1%	389	$89K
86704		<1%	4,858	$89K
73562		<1%	3,501	$88K
84153		<1%	4,629	$88K
75561		<1%	167	$88K
94618		<1%	2,421	$88K
73130		<1%	2,647	$87K
77080		<1%	3,453	$87K
J9045	Injection, carboplatin, 50 mg	<1%	1,900	$87K
J9395	Injection, fulvestrant, 25 mg	<1%	175	$86K
87070		<1%	4,734	$85K
82977		<1%	8,362	$84K
74018		<1%	2,758	$84K
76937		<1%	1,716	$84K
93454		<1%	93	$84K
87522	Neg quan hep c or qual rna	<1%	1,737	$83K
J2182	Injection, mepolizumab, 1 mg	<1%	26	$82K
36415	Collection of venous blood by venipuncture	<1%	52,324	$80K
93990		<1%	472	$80K
J0131	Injection, acetaminophen, not otherwise specified,10 mg	<1%	1,709	$80K
82105		<1%	4,806	$79K
77073		<1%	3,506	$78K
Q5118	Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg	<1%	93	$78K
0001A		<1%	2,191	$78K
J1750	Injection, iron dextran, 50 mg	<1%	420	$78K
0002A		<1%	1,966	$77K
J1170	Injection, hydromorphone, up to 4 mg	<1%	7,357	$75K
77065	Tomosynthesis, mammo	<1%	871	$75K
86334		<1%	4,828	$75K
86665		<1%	2,066	$74K
J3010	Injection, fentanyl citrate, 0.1 mg	<1%	9,115	$74K
82565		<1%	12,124	$74K
83883		<1%	4,783	$74K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	2,201	$71K
76870		<1%	948	$70K
84702		<1%	3,892	$70K
82746		<1%	3,700	$68K
72195		<1%	237	$67K
73552		<1%	1,525	$65K
82570		<1%	13,900	$65K
93925		<1%	448	$65K
81003		<1%	15,629	$65K
73564		<1%	1,484	$64K
96409		<1%	1,158	$64K
87536		<1%	828	$63K
73502		<1%	2,049	$63K
86706		<1%	3,715	$62K
J9190	Injection, fluorouracil, 500 mg	<1%	2,764	$62K
90715		<1%	2,036	$61K
J1885	Injection, ketorolac tromethamine, per 15 mg	<1%	10,660	$61K
43239	Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple	<1%	438	$60K
72100		<1%	2,228	$59K
86301		<1%	3,868	$58K
A9595	Piflufolastat f-18, diagnostic, 1 millicurie	<1%	15	$57K
72170		<1%	1,962	$57K
97112	Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination	<1%	4,750	$56K
96910		<1%	1,586	$56K
J9263	Injection, oxaliplatin, 0.5 mg	<1%	1,499	$56K
81479	Unlisted molecular pathology procedure	<1%	498	$55K
97140	Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage)	<1%	5,543	$55K
J9267	Injection, paclitaxel, 1 mg	<1%	1,276	$54K
82550		<1%	5,362	$54K
77387		<1%	666	$54K
90686		<1%	2,605	$53K
86360		<1%	1,282	$52K
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	3,236	$52K
A9585	Injection, gadobutrol, 0.1 ml	<1%	6,998	$51K
93922		<1%	659	$51K
73080		<1%	1,543	$50K
86304		<1%	2,834	$50K
82805		<1%	1,176	$49K
Z7610		<1%	15,256	$49K
82670		<1%	1,064	$47K
93321		<1%	1,138	$46K
J9202	Goserelin acetate implant, per 3.6 mg	<1%	37	$46K
J1100	Injection, dexamethasone sodium phosphate, 1 mg	<1%	5,858	$46K
J9201	Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg	<1%	1,459	$46K
95700		<1%	109	$46K
95708		<1%	56	$45K
86359		<1%	1,308	$45K
86235		<1%	1,056	$44K
95913		<1%	112	$44K
77280		<1%	543	$44K
86160		<1%	2,245	$44K
85652		<1%	11,316	$44K
96139		<1%	206	$43K
93926		<1%	413	$43K
81025		<1%	4,593	$43K
88184		<1%	907	$43K
J2930	Injection, methylprednisolone sodium succinate, up to 125 mg	<1%	1,980	$42K
73560		<1%	1,618	$41K
J2704	Injection, propofol, 10 mg	<1%	3,863	$41K
82607		<1%	5,174	$41K
G0500	Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate)	<1%	615	$40K
J9171	Injection, docetaxel, 1 mg	<1%	271	$40K
95886		<1%	531	$40K
99213	Doctor's office visit, returning patient (routine)	<1%	655	$40K
J3475	Injection, magnesium sulfate, per 500 mg	<1%	5,103	$40K
88360		<1%	763	$40K
J1200	Injection, diphenhydramine hcl, up to 50 mg	<1%	6,897	$39K
82248		<1%	5,340	$39K
86038		<1%	2,891	$39K
93225		<1%	761	$39K
85384		<1%	1,753	$39K
77370		<1%	187	$38K
91122		<1%	429	$38K
73501		<1%	1,516	$38K
66984	Extracapsular cataract removal with insertion of intraocular lens prosthesis	<1%	237	$38K
36430		<1%	419	$38K
86977		<1%	717	$38K
J3111	Injection, romosozumab-aqqg, 1 mg	<1%	24	$37K
74019		<1%	639	$37K
86708		<1%	2,181	$36K
84550		<1%	5,103	$36K
64615		<1%	1,247	$36K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	929	$36K
J0696	Injection, ceftriaxone sodium, per 250 mg	<1%	4,792	$35K
0012A		<1%	913	$35K
74220		<1%	708	$35K
72040		<1%	1,121	$35K
J9075	Injection, cyclophosphamide, not otherwise specified, 5 mg	<1%	201	$34K
J1815	Injection, insulin, per 5 units	<1%	1,128	$33K
96377		<1%	809	$33K
86769		<1%	833	$33K
J0780	Injection, prochlorperazine, up to 10 mg	<1%	2,960	$32K
84432		<1%	1,563	$32K
94726		<1%	614	$31K
96133		<1%	199	$31K
92014	Ophthalmological services: medical examination and evaluation, comprehensive, established patient	<1%	2,861	$31K
88307		<1%	333	$31K
94644		<1%	758	$30K
J2785	Injection, regadenoson, 0.1 mg	<1%	171	$30K
J0134	Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg	<1%	769	$30K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	382	$30K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	610	$30K
92012	Ophthalmological services: medical examination and evaluation, intermediate, established patient	<1%	1,501	$29K
0011A		<1%	974	$29K
76604		<1%	502	$29K
86225		<1%	1,658	$29K
76882		<1%	1,014	$29K
72082		<1%	734	$28K
86664		<1%	1,145	$28K
J2250	Injection, midazolam hydrochloride, per 1 mg	<1%	5,751	$28K
88312		<1%	776	$28K
78306		<1%	169	$27K
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine	<1%	4,804	$27K
87205		<1%	3,195	$27K
91065		<1%	499	$27K
83525		<1%	1,550	$27K
J2270	Injection, morphine sulfate, up to 10 mg	<1%	2,823	$26K
86787		<1%	1,123	$26K
J3489	Injection, zoledronic acid, 1 mg	<1%	795	$26K
90694		<1%	1,712	$26K
83516		<1%	2,211	$26K
84132		<1%	2,911	$25K
96116		<1%	343	$25K
84425		<1%	1,508	$25K
85045		<1%	4,856	$25K
80069		<1%	2,791	$25K
86870		<1%	695	$24K
70552		<1%	47	$24K
A9581	Injection, gadoxetate disodium, 1 ml	<1%	144	$24K
73090		<1%	816	$24K
84295		<1%	2,711	$23K
87102		<1%	1,571	$23K
94010		<1%	359	$23K
86780		<1%	2,144	$23K
80177		<1%	1,882	$23K
84156		<1%	6,425	$23K
J9070	Cyclophosphamide, 100 mg	<1%	101	$22K
96368		<1%	591	$22K
76512		<1%	444	$22K
82947		<1%	2,979	$22K
76801		<1%	282	$21K
82330		<1%	1,174	$21K
A9502	Technetium tc-99m tetrofosmin, diagnostic, per study dose	<1%	284	$21K
86663		<1%	1,134	$21K
0003A		<1%	517	$21K
92134		<1%	10,730	$21K
81373		<1%	135	$20K
88142		<1%	2,184	$20K
92567		<1%	1,350	$20K
93280		<1%	1,305	$20K
87116		<1%	1,271	$20K
80076		<1%	1,814	$20K
73140		<1%	953	$20K
95819		<1%	93	$20K
J2919	Injection, methylprednisolone sodium succinate, 5 mg	<1%	414	$20K
31231		<1%	1,173	$19K
88323		<1%	438	$19K
85014		<1%	3,000	$19K
82042		<1%	7,509	$19K
83001		<1%	743	$18K
J2765	Injection, metoclopramide hcl, up to 10 mg	<1%	2,876	$18K
86141		<1%	1,654	$18K
90732		<1%	344	$18K
97116		<1%	1,290	$18K
80195		<1%	1,182	$18K
11043		<1%	795	$18K
31579		<1%	497	$17K
95911		<1%	52	$17K
36592		<1%	284	$17K
71271		<1%	259	$17K
J1644	Injection, heparin sodium, per 1000 units	<1%	2,565	$17K
82140		<1%	858	$17K
88240		<1%	998	$17K
86255		<1%	629	$17K
A9541	Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries	<1%	270	$17K
76775		<1%	219	$16K
85651		<1%	1,934	$16K
90750		<1%	80	$16K
51798		<1%	1,883	$16K
84480		<1%	788	$16K
74230		<1%	300	$16K
J2001	Injection, lidocaine hcl for intravenous infusion, 10 mg	<1%	3,943	$16K
92612		<1%	130	$16K
73060		<1%	519	$15K
94621		<1%	51	$15K
83695		<1%	1,358	$15K
J3301	Injection, triamcinolone acetonide, not otherwise specified, 10 mg	<1%	1,465	$15K
83010		<1%	1,031	$15K
92083		<1%	2,959	$15K
96132		<1%	169	$15K
0064A		<1%	412	$15K
87529		<1%	351	$15K
74328		<1%	59	$14K
86705		<1%	983	$14K
99214	Doctor's office visit, returning patient (more involved)	<1%	411	$14K
88173		<1%	222	$14K
73718		<1%	73	$14K
P9016	Red blood cells, leukocytes reduced, each unit	<1%	52	$14K
90670		<1%	165	$14K
87493		<1%	458	$14K
J1642	Injection, heparin sodium, (heparin lock flush), per 10 units	<1%	1,347	$14K
88304		<1%	582	$14K
92504		<1%	839	$13K
86696		<1%	850	$13K
92526		<1%	467	$13K
86695		<1%	850	$13K
86644		<1%	992	$13K
86003		<1%	115	$13K
70480		<1%	68	$13K
86357		<1%	397	$12K
J1650	Injection, enoxaparin sodium, 10 mg	<1%	1,652	$12K
86592		<1%	2,258	$12K
90675		<1%	31	$12K
80175		<1%	1,057	$12K
83090		<1%	833	$11K
86355		<1%	396	$11K
J1790	Injection, droperidol, up to 5 mg	<1%	771	$11K
76942		<1%	152	$11K
88112		<1%	270	$11K
82150		<1%	761	$11K
91200		<1%	388	$11K
94727		<1%	305	$11K
95983		<1%	275	$11K
36591		<1%	859	$11K
70481		<1%	24	$10K
86431		<1%	1,377	$10K
72110		<1%	294	$10K
92020		<1%	726	$10K
J1940	Injection, furosemide, up to 20 mg	<1%	1,972	$10K
97162		<1%	787	$10K
M0222	Intravenous injection, bebtelovimab, includes injection and post administration monitoring	<1%	41	$10K
J2060	Injection, lorazepam, 2 mg	<1%	1,652	$10K
83993		<1%	637	$10K
99282	Emergency department visit for the evaluation and management, low to moderate severity	<1%	193	$10K
97163		<1%	353	$9K
92136		<1%	862	$9K
97803		<1%	1,230	$9K
95800		<1%	62	$9K
83921		<1%	903	$9K
J9206	Injection, irinotecan, 20 mg	<1%	296	$9K
94645		<1%	117	$9K
J0640	Injection, leucovorin calcium, per 50 mg	<1%	192	$9K
96138		<1%	204	$9K
J0690	Injection, cefazolin sodium, 500 mg	<1%	1,344	$8K
84146		<1%	276	$8K
95910		<1%	29	$8K
82040		<1%	1,443	$8K
92523		<1%	64	$8K
J0885	Injection, epoetin alfa, (for non-esrd use), 1000 units	<1%	110	$8K
82107		<1%	133	$8K
70487		<1%	13	$8K
86308		<1%	696	$7K
89050		<1%	778	$7K
90662		<1%	1,089	$7K
84478		<1%	722	$7K
87206		<1%	1,237	$7K
86335		<1%	445	$7K
73200		<1%	41	$7K
95885		<1%	139	$7K
84703		<1%	297	$7K
97161		<1%	735	$7K
45380	Colonoscopy, flexible; with biopsy, single or multiple	<1%	145	$7K
M0247	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring	<1%	19	$7K
97530	Therapeutic activities, direct patient contact, each 15 minutes	<1%	2,025	$7K
84630		<1%	496	$6K
88237		<1%	94	$6K
70355		<1%	170	$6K
80074		<1%	65	$6K
G0279	Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066)	<1%	1,142	$6K
72190		<1%	116	$6K
92585		<1%	24	$6K
95924		<1%	39	$6K
76519		<1%	170	$6K
87533		<1%	104	$6K
96376		<1%	1,017	$6K
72070		<1%	134	$6K
76815	Ultrasound, pregnant uterus, real time with image documentation, limited	<1%	66	$6K
C1769	Guide wire	<1%	187	$5K
86147		<1%	130	$5K
M0220	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring	<1%	34	$5K
71020		<1%	104	$5K
73521		<1%	135	$5K
92133		<1%	2,766	$5K
86146		<1%	129	$5K
85347		<1%	252	$5K
82010		<1%	395	$5K
73000		<1%	142	$5K
87081		<1%	479	$5K
87015		<1%	471	$5K
82610		<1%	429	$5K
85670		<1%	616	$5K
90656		<1%	200	$5K
82525		<1%	395	$5K
31575		<1%	123	$5K
82785		<1%	227	$5K
92201		<1%	169	$5K
0301		<1%	59	$4K
72050		<1%	99	$4K
80158		<1%	300	$4K
76380		<1%	41	$4K
J2997	Injection, alteplase recombinant, 1 mg	<1%	15	$4K
82274		<1%	710	$4K
99215	Doctor's office visit, returning patient (complex)	<1%	58	$4K
84300		<1%	603	$4K
77399		<1%	84	$4K
0053A		<1%	93	$4K
76881		<1%	43	$4K
88365		<1%	38	$4K
80299		<1%	184	$3K
0071A		<1%	85	$3K
93284		<1%	101	$3K
J0136	Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg	<1%	299	$3K
20610		<1%	104	$3K
0305		<1%	67	$3K
84590		<1%	229	$3K
17311		<1%	90	$3K
76805	Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation	<1%	30	$3K
82390		<1%	241	$3K
92604		<1%	48	$3K
80164		<1%	216	$3K
88377		<1%	16	$3K
95909		<1%	14	$3K
86777		<1%	166	$3K
93242		<1%	165	$3K
G0108	Diabetes outpatient self-management training services, individual, per 30 minutes	<1%	48	$3K
77001		<1%	25	$3K
J2371	Injection, phenylephrine hydrochloride, 20 micrograms	<1%	192	$3K
0072A		<1%	70	$3K
85613		<1%	168	$3K
86200		<1%	485	$3K
76514		<1%	972	$3K
A4649	Surgical supply; miscellaneous	<1%	17	$3K
J2920	Injection, methylprednisolone sodium succinate, up to 40 mg	<1%	203	$3K
45385	Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s)	<1%	56	$3K
11042	Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm	<1%	210	$3K
0051A		<1%	66	$3K
J0173	Injection, epinephrine (belcher), not therapeutically equivalent to j0171, 0.1 mg	<1%	98	$3K
86376		<1%	182	$3K
J0171	Injection, adrenalin, epinephrine, 0.1 mg	<1%	272	$3K
92225		<1%	59	$3K
73120		<1%	175	$3K
91010		<1%	93	$2K
90999	Dialysis (unlisted procedure)	<1%	13	$2K
83520		<1%	177	$2K
J3420	Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg	<1%	564	$2K
A9503	Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries	<1%	129	$2K
90739		<1%	14	$2K
0278		<1%	36	$2K
81002		<1%	776	$2K
C1894	Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser	<1%	80	$2K
82085		<1%	267	$2K
74240		<1%	38	$2K
20611		<1%	78	$2K
84402		<1%	65	$2K
G0498	Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted living) using a portable pump provided by the office/clinic, includes follow up office/clinic visit at the conclusion of the infusion	<1%	16	$2K
86148		<1%	78	$2K
82985		<1%	173	$2K
92226		<1%	42	$2K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	5,517	$2K
0636		<1%	48	$2K
85390		<1%	172	$2K
J2370	Injection, phenylephrine hcl, up to 1 ml	<1%	127	$2K
J1250	Injection, dobutamine hydrochloride, per 250 mg	<1%	137	$2K
84460		<1%	245	$2K
92273		<1%	13	$2K
73100		<1%	118	$2K
88264		<1%	26	$2K
82103		<1%	132	$1K
A9500	Technetium tc-99m sestamibi, diagnostic, per study dose	<1%	15	$1K
92229		<1%	84	$1K
J7040	Infusion, normal saline solution, sterile (500 ml = 1 unit)	<1%	256	$1K
93283		<1%	39	$1K
71010		<1%	19	$1K
83002		<1%	53	$1K
88313		<1%	57	$1K
J9060	Injection, cisplatin, powder or solution, 10 mg	<1%	44	$1K
80169		<1%	156	$1K
93978		<1%	13	$1K
J0137	Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg	<1%	83	$1K
31645		<1%	38	$1K
73600		<1%	47	$1K
97802		<1%	165	$1K
82232		<1%	103	$1K
J0665	Injection, bupivicaine, not otherwise specified, 0.5 mg	<1%	173	$1K
92060		<1%	116	$1K
90653		<1%	260	$1K
84134		<1%	64	$1K
92002		<1%	25	$1K
84681		<1%	43	$1K
82747		<1%	55	$1K
64566		<1%	71	$1K
86880		<1%	90	$1K
86036		<1%	44	$1K
J2003	Injection, lidocaine hydrochloride, 1 mg	<1%	136	$1K
86039		<1%	85	$998.04
90791	Psychiatric diagnostic evaluation	<1%	13	$984.40
76999		<1%	15	$980.00
J0461	Injection, atropine sulfate, 0.01 mg	<1%	54	$974.26
92025		<1%	577	$931.44
G2066	Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results	<1%	34	$916.45
91322		<1%	199	$881.81
82310		<1%	165	$879.00
83935		<1%	120	$873.88
82542		<1%	25	$860.88
84165		<1%	100	$854.84
0306		<1%	27	$846.53
83930		<1%	91	$842.56
86015		<1%	67	$839.46
73620		<1%	28	$834.56
J1953	Injection, levetiracetam, 10 mg	<1%	48	$820.62
G0499	Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result	<1%	221	$818.90
88280		<1%	26	$797.16
J1171	Injection, hydromorphone, 0.1 mg	<1%	154	$795.06
90480		<1%	206	$766.65
G0008	Administration of influenza virus vaccine	<1%	2,295	$765.08
87184		<1%	63	$723.42
83519		<1%	108	$689.22
36600		<1%	105	$658.23
67228		<1%	12	$641.46
84207		<1%	41	$637.22
86635		<1%	44	$606.20
84520		<1%	109	$606.01
0949		<1%	33	$604.72
82465		<1%	67	$600.22
95836		<1%	13	$595.93
88172		<1%	49	$587.24
J1010	Injection, methylprednisolone acetate, 1 mg	<1%	38	$563.20
93298		<1%	13	$558.04
88311		<1%	83	$540.39
84270		<1%	13	$535.94
82272		<1%	192	$497.81
99205	Prolong outpt/office vis	<1%	13	$493.90
97003		<1%	13	$492.32
J1720	Injection, hydrocortisone sodium succinate, up to 100 mg	<1%	19	$478.96
0324		<1%	13	$461.19
91037		<1%	12	$455.51
0031A		<1%	13	$445.00
86902		<1%	34	$441.87
0296T		<1%	90	$431.72
82787		<1%	13	$426.57
86381		<1%	38	$411.16
86905		<1%	13	$409.46
84155		<1%	155	$404.48
J1030	Injection, methylprednisolone acetate, 40 mg	<1%	29	$400.47
G0121	Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk	<1%	12	$392.37
97535	Self-care/home management training, each 15 minutes	<1%	96	$385.65
83721		<1%	38	$378.44
87338		<1%	112	$335.68
92004	Ophthalmological services: medical examination and evaluation, comprehensive, new patient	<1%	24	$334.23
84450		<1%	27	$327.75
95874		<1%	14	$317.44
82340		<1%	45	$302.82
J9370	Vincristine sulfate, 1 mg	<1%	17	$287.79
17110		<1%	102	$284.37
92235		<1%	12	$273.64
92285		<1%	59	$265.14
82668		<1%	12	$243.31
11900		<1%	55	$238.45
84446		<1%	12	$234.84
J3370	Injection, vancomycin hcl, 500 mg	<1%	20	$225.81
G1004	Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program	<1%	4,084	$207.44
89051		<1%	32	$194.10
J1836	Injection, metronidazole, 10 mg	<1%	17	$123.35
96379		<1%	1,036	$112.58
J2305	Injection, nitroglycerin, 5 mg	<1%	12	$111.16
Q0162	Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen	<1%	48	$101.78
Q9963	High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml	<1%	12	$98.52
J2470	Injection, pantoprazole sodium, 40 mg	<1%	20	$74.14
82247		<1%	14	$73.25
93010	Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only	<1%	36	$64.00
69210		<1%	12	$61.78
J2795	Injection, ropivacaine hydrochloride, 1 mg	<1%	78	$60.96
J2550	Injection, promethazine hcl, up to 50 mg	<1%	15	$54.70
J7120	Ringers lactate infusion, up to 1000 cc	<1%	13	$53.54
82435		<1%	26	$51.27
J7070	Infusion, d5w, 1000 cc	<1%	76	$47.45
82523		<1%	50	$43.89
11721		<1%	25	$42.83
84080		<1%	65	$38.78
97010		<1%	20	$25.96
C9257	Injection, bevacizumab, 0.25 mg	<1%	80	$14.59
80235		<1%	13	$12.23
G0009	Administration of pneumococcal vaccine	<1%	351	$9.91
J3480	Injection, potassium chloride, per 2 meq	<1%	19	$0.85
Q0247	Injection, sotrovimab, 500 mg	<1%	18	$0.11
0250R		0%	236	$0.00
G8980	Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting	0%	62	$0.00
0134A		0%	46	$0.00
91306		0%	15	$0.00
91301		0%	15	$0.00
G8985	Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	0%	65	$0.00
G8979	Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	0%	343	$0.00
G8996	Swallowing functional limitation, current status at therapy episode outset and at reporting intervals	0%	12	$0.00
G8978	Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals	0%	331	$0.00
G8984	Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals	0%	38	$0.00
0124A		0%	15	$0.00
G8997	Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	0%	12	$0.00
90780		0%	27	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialSARAO, GURINDER (LEAD CREDENTIALING ASSISTANT)